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802Objectives: The optimal management of dilated ascending aorta during aortic valve replacement (AVR)
remains controversial. This study compared the outcomes among 3 different managements (AVR alone, aorta
wrapping, and aorta replacement) for the dilated ascending aorta.
Methods: The study enrolled 499 consecutive non-Marfan patients undergoing AVR in the presence of the
ascending aorta dilatation (40 to 55mm).We evaluated rates of death and aortic events; in addition, we evaluated
the aortic expansion rate by serial echocardiography.
Results: The surgery involved AVR alone (n ¼ 362), aorta wrapping (n ¼ 67), or aorta replacement (n ¼ 70).
Early mortality occurred in 1.2% (n ¼ 6, P ¼ .61). Throughout 1590.0 patient-years of follow-up, 47 deaths
occurred. The 5-year survival rates were 90.1% 2.0%, 91.8% 3.5%, and 82.2% 7.5% in the AVR alone,
aorta wrapping, and aorta replacement groups, respectively (P¼ .64). One aortic event (acute type A dissection)
occurred in the AVR alone group. For the AVR alone group, the median aortic expansion rate was 0.6 mm/y
(interquartile range, 3.2 to 0.6 mm/y). The aortic expansion rates were affected neither by the morphology of
aortic valves (bicuspid vs tricuspid; P ¼ .10) nor by the initial aorta diameter (g ¼ 0.31, P ¼ .61). Clinically
relevant aortic expansion (5 mm/y) was observed only in 5 patients; of these patients, 2 showed the aortic
diameter of 60 mm or greater at the end of follow-up.
Conclusions: Compared with concomitant aortic wrapping or replacement, AVR alone achieved similar clinical
outcomes, showing considerably low risks of adverse aortic events or relevant aortic expansion in dilated ascend-
ing aorta. These findings argue against routine aortic replacement at the time of AVR. (J Thorac Cardiovasc Surg
2013;146:802-9)A significant proportion of patients undergoing aortic valve
replacement (AVR) are reported to have a dilated ascending
aorta.1 Several observational studies have shown that an
untreated ascending aorta aneurysm may predispose to fatal
aortic dissection or rupture2,3; consequently, practice
guidelines recommend performing aortic replacement at
the time of AVR if the aortic diameter is greater than
45 mm, especially in patients with a bicuspid aortic valve
(BAV).4,5 These guidelines are further supported by
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The Journal of Thoracic and Cardiovascular Surghemodynamic turbulences caused by aortic valve diseases
but is also attributable to the intrinsic pathology of the
aortic wall.6-9 Because AVR treats only the hemodynamic
abnormalities, and not the intrinsic aortopathy, aorta
replacement during AVR has been regarded as
a reasonable option in patientswith a dilated ascending aorta.
More recent studies, however, have shown that patients
undergoing isolated AVR in the presence of the ascending
aorta dilation are at a considerably low risk of adverse aortic
events throughout long-term follow-up, raising arguments
against routine replacement of the aorta at the time of
AVR, even in BAV.10-13 Furthermore, a recent large-scale
clinical study using echocardiographic evaluations revealed
that a long-term hemodynamic burden is the most important
contributing factor of aortic dilatation in BAV and that
isolated AVR is an effective method to prevent pathologic
progression.14 These findings suggest that recommenda-
tions in current guidelines should be reevaluated through
further clinical investigations and better data analysis.
In this study,we sought to compare clinical outcomesofpa-
tients undergoing AVR in the presence of a dilated ascending
aorta, according to the different methods of managing the
ascending aorta (AVR alone, aorta wrapping, and aorta
replacement) in a reasonably sized cohort. Furthermore, weery c October 2013
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
CT ¼ computed tomographic
IQR ¼ interquartile range
LV ¼ left ventricular
TAV ¼ tricuspid aortic valve
Lee et al Acquired Cardiovascular Diseaseevaluated the changes in sizes of the native ascending aorta
through data from serial echocardiographic assessments.A
C
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Patients
From January 2001 through December 2011, a total of 2076 patients
underwent AVR at the Asan Medical Center (Seoul, Korea). Of these
patients, those with Marfan/Ehlers-Danlos syndrome or those who had
aortic root aneurysm requiring concomitant aortic root replacement were
excluded. Finally, we retrieved 499 patients who had a dilated ascending
aorta (defined as 40-55 mm in its maximal diameter, based on preoperative
echocardiographic assessments), and these patients formed the subject
population of this study. Regarding the surgical management of the dilated
ascending aorta, 362 patients (72.5%) underwent AVR alone, 67 (13.4%)
underwent ascending aorta wrapping using prosthetic vascular grafts, and
70 (14.0%) underwent concomitant ascending aorta replacement. The
decision to perform concomitant aortic procedures was affected by the
aortic size, the morphology of the AV (bicuspid [BAV] vs tricuspid
[TAV]), and expected surgical risks manifested by left ventricular (LV)
functions, but was finally at the discretion of the attending surgeon.
This study was approved by the Ethics Committee/Review Board of the
Asan Medical Center, and the committee waived the requirement for
informed consent from the individual patient because of the retrospective
nature of the study.
Surgical Technique
Median sternotomy (n ¼ 475), upper hemisternotomy (n ¼ 18), or
transverse sternotomy (n ¼ 6) approaches were used according to the
surgeon’s preferences. The distal ascending aorta (n ¼ 466) was the
most common site for the arterial cannulation, whereas femoral artery
cannulation was used in some patients (n ¼ 10) undergoing minimally
invasive approaches. In patients who were judged to replace the aorta
beyond the distal ascending aorta (n ¼ 23), the right axillary artery was
used for the cannulation.
For patients undergoing concomitant aorta replacement, 24- to 34-mm
(median, 28-mm) commercially available vascular grafts were used for
aorta replacement. In patients requiring open distal aorta anastomosis,
antegrade selective cerebral perfusion was used during circulatory arrest
under moderate systemic hypothermia.
For patients receiving the aorta wrapping technique, 26- to 34-mm
(median, 32-mm) vascular grafts were used to surround the native ascend-
ing aorta. The aorta wrapping procedure was done after the completion
of hemostasis and protamine reversal after the AVR. The length of the
vascular graft was determined according to the distance between the
sinotubular junction and the origin of the innominate artery. After the
longitudinal incision of the graft, the native ascending aorta was
surrounded by the graft, and the incised portion of the graft was reattached
at the anterior side of the aorta using 4-0 or 3-0 polypropylene (Prolene)
sutures (Ethicon, Inc, Somerville, NJ). To prevent graft migration, several
fixation stitches were made on the aortic adventitia at most proximal and
distal parts of the graft.The Journal of Thoracic and CaFollow-up
The primary outcomes of interest were all-cause death and adverse
aortic events, the latter including aortic dissection/rupture, reoperation of
the proximal aorta, and sudden death. Data were obtained through June
2012, during regular visits to the outpatient clinic. For validation of
complete follow-up information regarding mortality, data on vital status,
and dates of death were obtained through June 2012 from the Korean
National Registry of Vital Statistics. Early mortality was defined as death
within 30 days of surgery. All deaths were considered of cardiovascular
origin unless a noncardiovascular origin was established clinically.
To assess the changes in maximal diameter of the ascending aorta in
patients who underwent AVR alone or aorta wrapping, serial postoperative
echocardiographic data were reviewed. Postoperative echocardiographic
assessments were routinely performed before discharge. Generally,
follow-up echocardiographic evaluations were done at 6 months, 1 year,
and then biennially thereafter. During the echocardiographic assessments,
the size of the ascending aorta was routinely measured through parasternal
long axis view. The difference in aortic diameters between ‘‘before
surgery’’ and ‘‘at last follow-up’’ was calculated, and this difference was
divided by follow-up duration to yield the aortic expansion rate.
Statistical Analysis
Categorical variables, presented as frequencies and percentages,
were compared using the c2 test. Continuous variables, expressed as
mean  SD or median with range, were compared using the analysis of
variance or Kruskal-Wallis test, as appropriate. The Kaplan-Meier method
was used to delineate the survival rate, and a log-rank test was used to
compare the differences in the rates among patient groups.
A Pearson correlation coefficient analysis was used to determine the
relationship between preoperative aortic diameter and postoperative
aortic expansion rate. All reported P values were 2 sided, and P< .05
was considered statistically significant. SPSS, version 18.0 (IBM Corp,
Armonk, NY), was used for the statistical analysis.RESULTS
Baseline Characteristics and In-Hospital Outcomes
Baseline demographic, clinical, and echocardiographic
parameters are detailed in Table 1. In summary, patients
who underwent concomitant aorta replacement were biased
toward female sex, were more likely to have aortic stenosis
and bicuspid aortic valves, and had a larger ascending aorta,
a higher LV ejection fraction, and smaller LV dimensions
compared with those who underwent AVR alone or aorta
wrapping. Aorta clamping and cardiopulmonary bypass
times were significantly longer in patients undergoing
AVR plus aorta replacement than in those undergoing aorta
wrapping and AVR alone. Of the patients whowere planned
to undergo AVR alone, 2 (0.5%) required aorta replacement
because of aortic injuries at the cannulation sites. (These
patients were categorized in the aortic replacement group.)
Early mortality occurred in 6 patients (1.2%; 5 in the AVR
alone group and 1 in the aortic wrapping group). Table 2
shows early postoperative outcomes of patients.Clinical Events: Adverse Aortic Outcomes
Clinical follow-up was complete in 469 patients
(94.0%), with a median follow-up duration of 43.6 months
(interquartile range [IQR], 24.5-68.8 months), whichrdiovascular Surgery c Volume 146, Number 4 803
TABLE 1. Baseline characteristics of patients
Characteristics AVR alone (n ¼ 362) Aorta wrapping (n ¼ 67) Aorta replacement (n ¼ 70) P value
Age, y 59.7  12.6 62.3  11.3 60.1  12.0 .25
Female sex 102 (28.2) 24 (35.8) 32 (45.7) .011
Diabetes mellitus 29 (8.0) 5 (7.5) 3 (4.3) .55
Hypertension 81 (22.4) 16 (23.9) 11 (15.7) .41
Chronic renal failure 9 (2.5) 1 (1.5) 1 (1.4) .78
Previous cardiac surgery 16 (4.4) 1 (1.5) 5 (7.1) .27
Urgent or emergent surgery 6 (1.7) 0 0 .68
Infective endocarditis 24 (6.6) 1 (1.5) 2 (2.9) .14
Aortic valve disease .034
AS 142 (39.2) 32 (47.8) 38 (54.3)
AR 141 (39.0) 14 (20.9) 19 (27.1)
Mixed ASR 78 (21.5) 21 (31.3) 13 (18.6)
No AS or AR 1 (0.3) 0 0
Bicuspid aortic valve 139 (38.4) 34 (50.7) 48 (68.6) <.001
Atrial fibrillation 34 (10.2) 9 (13.4) 7 (10.0) .72
Maze procedure 16 (4.4) 5 (7.5) 2 (2.9) .42
Maximal aorta diameter, mm 43.1  2.9 46.0  3.4 47.5  4.1 <.001
40,<45 260 (71.8) 25 (37.3) 21 (30.0)
45,<50 88 (24.3) 30 (44.8) 24 (34.3)
50-55 14 (3.9) 12 (17.9) 25 (35.7)
Echocardiographic data
LV EF,% 54.0  12.5 54.7  12.5 59.3  9.7 .007
LVDs, mm 40.2  11.9 38.3  11.5 35.7  9.7 .014
LVDd, mm 58.4  11.5 55.0  10.0 55.1  9.3 .020
LV mass, g 301.7  100.2 292.7  78.6 276.6  82.3 .15
Peak TR PG, mmHg 27.5  14.0 26.6  12.2 23.4  11.1 .094
Concomitant CABG 45 (12.4) 7 (10.4) 10 (14.3) .79
Cardiac ischemic time, min 71.9  27.9 74.0  27.7 118.2  47.1 <.001
Total pump time, min 116.3  46.9 128.4  49.0 182.2  71.0 <.001
Values are given as number (%) unless otherwise indicated. AVR, Aortic valve replacement; AS, aortic stenosis; AR, aortic regurgitation; ASR, aortic stenoregurgitation; LV, left
ventricle; EF, ejection fraction; LVDs, left ventricular systolic dimension; LVDd, left ventricular diastolic dimension; TR PG, tricuspid regurgitation pressure gradient; CABG,
coronary artery bypass grafting.
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Dcomprised 1590.0 patient-years of follow-up. During the
late period, 40 patients died (27 in the AVR alone group,
6 in the wrapping group, and 7 in the replacement group).
Cardiovascular causes of death (n ¼ 26) were as follows:
congestive heart failure (n ¼ 4), infective endocarditis
(n ¼ 4), acute aortic dissection (n ¼ 1) (previously men-
tioned), descending aortic aneurysm (n ¼ 2, 1 rupture
case and 1 surgical mortality), stroke (n ¼ 1), ventricular
arrhythmia (n ¼ 1), and unknown cause (n ¼ 13). Causes
of noncardiovascular deaths (n ¼ 14) were malignancy
(n¼ 8), complications related to chronic renal insufficiencyTABLE 2. Early postoperative complications
Variables AVR alone (n ¼ 362) Aorta wr
Re-exploration for bleeding 12 (3.3)
Requirement for dialysis 3 (0.8)
LCOS* 4 (1.1)
Neurologic deficity 2 (0.6)
Complete AV block 2 (0.6)
Values are given as number (%) unless otherwise indicated. AVR, Aortic valve replacem
supports, such as intra-aortic balloon pumping or extracorporeal life support. yIncludes 1
804 The Journal of Thoracic and Cardiovascular Surg(n ¼ 3), pneumonia (n ¼ 2), and suicide (n ¼ 1). Overall
5-year survival rates were 90.1%  2.0%, 91.8% 
3.5%, and 82.2% 7.5% in the AVR alone, the wrapping,
and the replacement groups, respectively, without signifi-
cant differences among the groups (P ¼ .64, Figure 1).
Furthermore, among patients who underwent AVR alone
(n ¼ 362), the overall survival rates did not significantly
differ between 2 patients groups, according to a cutoff of
45 mm for baseline ascending aorta diameter (Figure 2).
One aortic dissection occurred in a patient who under-
went AVR alone for severe AR (tricuspid aortic valve).apping (n ¼ 67) Aorta replacement (n ¼ 70) P value
1 (1.5) 4 (5.7) .39
1 (1.5) 0 .62
1 (1.5) 0 .64
1 (1.5) 0 .52
1 (1.5) 0 .52
ent; LCOS, low cardiac output syndrome; AV, aortic valve. *Requiring mechanical
permanent (AVR-alone group) and 2 transient deficits.
ery c October 2013
FIGURE 1. Kaplan-Meier survival curves according to the management
for the ascending aorta. AVR, Aortic valve replacement.
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the time of AVR, and he underwent emergent surgery for
acute type I aortic dissection that occurred 1731 days after
initial surgery. He eventually died of neurologic damages
after the emergent aortic surgery. There was no case of
proximal aorta reoperation, except for the patient who
had acute aortic dissection. Including 5 patients who
died suddenly or of unknown causes, overall 6 cases of
adverse aortic events occurred in the AVR alone group.
The linearized rate of the adverse aortic events for AVR
alone was 0.5% per patient-year.
Changes in Aortic Diameter
Echocardiographic evaluations in the late period
(>6 months) were available in 404 patients of 488 late
(>6 months) survivors (82.8%). Median echocardiographic
follow-up duration was 24.9 months (IQR, 12.6-47.9
months), and the duration was significantly longer withFIGURE 2. Kaplan-Meier survival curves of patients who underwent
isolated aortic valve replacement (n ¼ 362) according to the ascending
aortic diameter at baseline.
The Journal of Thoracic and Cathe AVR alone (34.1  28.0 months) or the wrapping
(37.5  21.7 months) groups compared with the replace-
ment group (25.9  21.0 months; P ¼ .017).
In the AVR alone group (echocardiographic follow-up:
n ¼ 290), the aortic expansion rate was 0.6 mm/y (IQR,
3.2 to 0.6 mm/y) and the maximal diameter of the ascend-
ing aorta at last follow-up was 40.9  7.3 mm. The
frequency distribution of the aortic expansion rate is illus-
trated in Figure 3. The aortic expansion rates were not
significantly different between BAV and TAV (P ¼ .10,
Table 3), or among stenosis, regurgitation, and mixed sten-
oregurgitation of the aortic valves (P¼ .084). Furthermore,
there was no significant correlation between initial maximal
aortic diameter and aortic expansion rate (g ¼ 0.31,
P ¼ .61, Figure 4). Five patients (1.7%) showed an aortic
expansion rate of more than 5mm/y, and all of these patients
had TAV, with a maximal aortic diameter of 40 to 43 mm at
baseline. At the end of follow-up, 2 patients (0.7%, 1 with
BAV and 1 with TAV, whose condition was complicated
with aortic dissection) showed an aorta diameter of more
than 60 mm. The patient with BAV (a 72-year-old man)
was recommended to undergo aorta replacement at 6 years
after initial surgery, but he refused the surgery and is
receiving conservative management.
In the wrapping group (echocardiographic follow-up:
n ¼ 54), the aortic expansion rate was 2.1 mm/y (IQR,
3.9 to 0.9 mm/y) and the maximal diameter of the
ascending aorta at last follow-up was 39.8  5.8 mm.
None of the patients in the wrapping group showed rapid
aortic expansion (>5 mm/y) or definite aneurysm formation
of the ascending aorta (>55-60 mm).DISCUSSION
In the present study, we found that adverse aortic events
were rare after AVR alone (0.5% per patient-year)FIGURE3. Frequencydistributionof aortic expansion rate during follow-up.
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TABLE 3. Preoperative and postoperative data of patients who
underwent aortic valve replacement alone according to the baseline
aortic valve morphology
Variables
BAV
(n ¼ 139)
TAV
(n ¼ 223)
P
value
Preoperative profiles
Aortic valve disease, no. (%) <.001
AS 84 (60.4) 58 (26.0)
AR 24 (17.3) 117 (52.5)
Mixed ASR 31 (22.3) 47 (21.1)
No AS or AR 0 1 (0.4)
Maximal aorta diameter, mm 43.1  2.6 43.1  3.0 .90
40,<45 100 (71.9) 160 (72.1)
45,<50 35 (25.2) 53 (23.9)
50-55 4 (2.9) 9 (4.1)
Postoperative profiles
Maximal aorta diameter
at last visit, mm
40.0  6.0 41.4  7.9 .10
Aortic expansion rate, mm/y 1.3
(3.0 to 2.1)
0.6
(1.7 to 1.9)
.10
BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve; AS, aortic stenosis; AR, aortic
regurgitation; ASR, aortic stenoregurgitation.
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Din patients with a dilated ascending aorta (40-55
mm), and the overall survival was not affected by the
aortic diameter at baseline. When patients were assessed
by serial echocardiography, clinically relevant aneurysm
formation or rapid expansion of the aorta was also rare,
and the aortic expansion rates did not significantly corre-
late with any of the following: morphology (TAV vsFIGURE 4. Aortic expansion rate according to the
806 The Journal of Thoracic and Cardiovascular SurgBAV) or valvulopathy (stenosis vs regurgitation) of the
aortic valves and the aortic diameter at baseline. Further-
more, the aortic wrapping technique was also helpful in
stabilization of the aorta, with excellent long-term durabil-
ity. Nevertheless, safety profiles of ascending aorta re-
placement during AVR were also acceptable, supporting
more liberal choices of aorta management based on the in-
dividual patient’s conditions (ie, expected surgical risks
and life expectancy).
According to practice guidelines pertaining to the man-
agement of ascending aorta during AVR, patients with
ascending aorta of greater than 45 mm should be considered
for concomitant replacement of the ascending aorta.4,5
Reviewing the reference supporting this recommendation,
only a single observational study exists.3 In the cited study,
the authors retrospectively reviewed 201 patients who
underwent AVR for BAV without aortic replacement. Of
the 201 patients, 64 had mild dilatation (40-44 mm) and
22 had moderate dilatation (45-49 mm) of the ascending
aorta. Because the authors learned that the 15-year freedom
from ascending aorta–related complications was 86%,
81%, and 43% in patients with an aortic diameter of less
than 40 mm, 40 to 44 mm, and 45 to 49 mm, respectively
(P<.001), they concluded that patients undergoing surgery
for BAV disease should be considered for concomitant
replacement of the ascending aorta if the diameter is
45 mm or greater. This cutoff value of ‘‘45 mm’’ has been
firmly accepted as touchstone in the management
of ascending aorta during AVR, and this suggestion wasinitial maximal diameter of the ascending aorta.
ery c October 2013
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AV diseases.6-9 In those studies, aortic dilatation is
attributable to hemodynamic turbulence caused by AV
disease and intrinsic abnormality of the aortic wall; thus,
the aorta is likely to further expand, even after correction
of AV diseases. The size-derived guidelines extended to
AVR in TAV, but no pertinent data available to date are in
support of this recommendation in TAV.
These size-derived current guidelines, however, are
limited by weaknesses of the key citing research, in that
despite the strength of long-term follow-up data, the results
are derived from retrospective observational data including
only a few patients in a single center.3 In particular, the
number of patients with a moderately dilated ascending
aorta (>45 mm) was only 22; the data are too small to
form a robust conclusion. In this regard, there have been
arguments on current practice guidelines that they should
be reevaluated through better data analysis, considering
the risk and benefit of concomitant replacement of the
aorta.10,12-14
More recent studies raised contradictions on routine
replacement of dilated ascending aorta during AVR.10-13
Gaudino and colleagues13 evaluated 93 patients with dila-
tion of the ascending aorta (50-59 mm) submitted to AVR
alone for TAV stenosis. Patients were observed for a mean
of 14.7  4.8 years, and no patients experienced adverse
aortic events or had to have the aorta reoperated on. Further-
more, there was no significant increase in aortic diameter,
with a mean ascending aorta expansion rate of 0.3  0.2
mm/y. The authors concluded that AVR alone is sufficient
in patients with poststenotic dilation of the ascending aorta
if connective tissue disorders are not present. Nevertheless,
leaving the aorta of nearly 60 mm in diameter during AVR
may be regarded as neither reasonable nor safe by most
practicing surgeons because the aortic size of 55 mm or
greater is regarded as a surgical indication by itself, even
in asymptomatic subjects with an isolated ascending aorta
aneurysm.
McKellar and colleagues10 retrospectively reviewed
1286 patients who underwent AVR for BAV without aortic
replacement or repair. During a median follow-up of 12
years, there were aortic dissections in 1%, ascending
aortic replacements in 0.9%, and documented cases of
progressive aortic enlargement in 9.9%, resulting in
15-year freedom from adverse aortic events of 89%. Of
the patients, quantitative data on preoperative ascending
aorta size were available in 323, of whom 248 had a normal
aorta (<40 mm), whereas 75 had a dilated ascending aorta
(>40 mm). When compared with those with a normal aorta,
the patients with a dilated aorta showed similar risks of
adverse aortic events (P ¼ .13), overall mortality
(P ¼ .67), and cardiovascular mortality (P ¼ .32). The
authors concluded that, although there was a true risk for
adverse aortic events after AVR for BAV, its incidenceThe Journal of Thoracic and Cawas low, and additional surgical risk imposed by con-
comitant aortic replacement should, therefore, be at least
equally low.
In support of their study, Girdauskas and colleagues12
conducted an analysis on 153 patients with BAV stenosis
and concomitant ascending aortic dilation (40-50 mm)
undergoing AVR alone. During a mean follow-up of
11.5  3.2 years, surgery on the ascending aorta was re-
quired in 5 patients (3%) for progressive ascending aortic
aneurysm, but no documented aortic dissection or rupture
occurred. Freedom from adverse aortic events was 93%
at 15 years postoperatively. The authors concluded that pa-
tients with BAV stenosis and concomitant mild-to-moderate
ascending aortic dilation are at a considerably low risk of
adverse aortic events during long-term follow-up after an
isolated AVR. Andrus and colleagues11 evaluated aortic
expansion rates after isolated AVR in 185 patients,
including both types of AV morphology (BAV and TAV).
Dilatation of the ascending aorta (>35 mm; range, 35-53
mm) was present in 107 patients (58%) at baseline, and
there was no significant increase in mean ascending aortic
diameter (40  4 vs 39  6 mm) or development of aortic
aneurysm (>55 mm) during follow-up in this subset of
patients.
Recent studies previously cited are in support of
a conservative approach in the management of a mild to mo-
derately dilated ascending aorta during AVR, which are in
agreement with the findings of the present study.10-13
Moreover, the overall survival was not affected by the
baseline aortic diameter (45 vs <45 mm) in patients
undergoing isolated AVR in the present study, the result
being discordant with the key citing reference in the
current guidelines.3 This needs to be verified by accumula-
tion of further clinical data. Finally, agreeing with McKellar
and colleagues,10 the feasibility of concomitant replace-
ment of the aorta should be evaluated through studies on
a larger population, considering the early surgical risks
and the long-term prophylactic benefits added by the aorta
replacement.
Aortic dilatation associated with BAV diseases has been
regarded as a result of a genetic disorder or inherited
fragility, and this knowledge has led to recommendations
that the proximal aorta in patients with BAV be replaced
more aggressively.6,8,9 In contrast, in a recent study,
a cross-sectional analysis of echocardiographic data was
undertaken in many patients (n¼ 595) with aortic valvulop-
athy, with longitudinal follow-up to evaluate the aortic
expansion rates.14 In the cited study, the annual dilatation
rates of the ascending aorta were significantly higher in
the patients with BAV not undergoing AVR compared
with those undergoing AVR for BAV or TAV diseases.
Furthermore, the aortic expansion rates did not differ
between the BAV and TAV groups when treated with
AVR. These findings of the protective effects of AVR inrdiovascular Surgery c Volume 146, Number 4 807
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major determinant of the development of aortopathy and,
thus, the reevaluation of recommendations in current
practice guidelines through better clinical investigations
and better data analysis was claimed by the authors.
Although computed tomographic (CT) scanning is the
gold standard method in the evaluation of the aorta, it
inevitably accompanies radiation hazards and, therefore, its
use as a tool for lifelong follow-up in patients with
reasonable life expectancy has been limited.15 Meanwhile,
echocardiography is a well-proven modality in accurately
measuring the size of the ascending aorta without such risks,
which is highly correlated with values obtained by CT
scans.16 Reflecting this general consensus, echocardio-
graphic data were available in most patients (82.8%) during
the late period, whereas the data from CT assessments were
limited to yield aortic expansion rate (<60% of follow-up)
in the present study. Echocardiographymeasures internal di-
ameters, whereasCTmeasures external diameters; therefore,
some allowance should be made for echocardiographic
measurements being smaller than CT measurements.17
Study Limitations
This study is subject to the limitations inherent to
a retrospective analysis of observational data. The decision
to perform procedures on the aorta was affected by patients’
preoperative conditions, in which patients undergoing AVR
alone tended to have TAV more frequently and to have
a smaller aortic diameter than those undergoing concomi-
tant aortic procedures. Moreover, only 14 patients who
had an aortic diameter of more than 50 mm underwent
AVR alone; therefore, statistical power regarding the
evaluation of safety profile of AVR alone in this patient
subset might have been limited to generalize the conclusion
to those having a relatively larger aorta.
Aortic size measurements were made with transthoracic
echocardiographic assessment, which is not the gold
standard method in aortic evaluations. In particular,
measurement variations may occur when the distal ascen-
ding aorta is evaluated. Limited durations of clinical and
echocardiographic follow-up are also important limitations
of this study. Not all patients could be assessed with
echocardiography in the late period. Longitudinal echo-
cardiographic assessments in these populations, however,
are inevitably limited because a significant proportion of
patients no longer need imaging assessments during
follow-up. These are the cases with stabilization or
regression in the aortic sizes in the AVR alone group
(65.9%).
The number of early mortalities was too small to evaluate
surgical risks added by the concomitant replacement of
ascending aorta with adequate statistical power. The safety
issue of concomitant aorta replacement should, therefore,
be addressed in further studies involving larger populations.808 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
Compared with concomitant aortic wrapping or replace-
ment, AVR alone achieved similar clinical outcomes,
showing considerably low risks of adverse aortic events
or relevant aortic expansion in dilated ascending aorta.
These findings argue against routine aortic replacement at
the time of AVR. Further large-scale studies are mandatory
to define proper indications of concomitant aorta replace-
ment during AVR, considering the surgical risks and
long-term benefits.
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DDiscussion
Dr Thoralf M. Sundt (Boston, Mass). Congratulations on
conducting what I think is an important study with profound
clinical implications.
Aortic dissection is a highly lethal condition without doubt, and
the results of aortic replacement have improved so much over the
course of the last decade or so that we, as cardiac surgeons, and
cardiac surgeons all around the world have become much more
aggressive about replacing even the moderately dilated aorta.
However, as you have pointed out, the data actually supporting
that practice are pretty thin.
You have chosen to study a population of all patients undergo-
ing aortic valve replacement who have moderate aortic dilatation,
although this is most often discussed in the setting of bicuspid
aortic valve. As you have noted, because BAV is so common,
the recommendations we make concerning the management of
patients with this condition turn out to impact a huge number of
patients.
Your results suggest that we should be more circumspect, that
the moderately dilated aorta need not be routinely replaced. This
is an important and useful counterpoint to the current trend. I
hope there will be a lot of discussion from the floor on this topic
because I do think it is an important one.
There are some challenges in interpreting your study, however,
and I would like to draw attention to several issues and ask several
questions. First, it is challenging any time intellectually, mentally,
when we are comparing 3, rather than just 2, treatment groups.
You have compared the results of AVR alone, AVR with aortic
replacement, and AVR with wrapping. In fact, in the West, aortic
wrapping is seldom, if ever, practiced. In the view of most surgeons
given modern graft material, aortic wrapping offers little advan-
tage over the more definitive procedure of aortic replacement.
So with your permission, I would want to focus only on 2
groups, the groups that we would most commonly deal with in
this country, AVR alone versus AVR with aortic replacement.
That leaves us with 70 patients with aortic replacement and 362
who had AVR alone.
If you focus on these 2 groups, they are of similar age and
similar functional valve pathology, but with female gender much
more common among those with replacement, and BAV almost
twice as common among those with aortic intervention.
Furthermore, the distribution of aortic diameter was actually
much different between these 2 groups, with over 70% of the
patients in the AVR-only group having aortas less than 45 mmThe Journal of Thoracic and Cacompared with less than a third of those in the aortic intervention
group having these small-sized aortas.
In fact, over one-third of the aortic replacement group had an
aorta over 5 cm compared with 4% in the no-aortic intervention
group.
So, my first question really is how do you see these 2 groups as
comparable? Are you not really comparing the outcome of AVR
alone with minimally enlarged aortas in the presence of a trileaflet
valve versus AVR plus aortic replacement in BAV disease?
Dr Kim. Thank you, Dr Sundt, for your important question. I
absolutely agreewith you that maybe 3, and 2, groups are not fairly
comparable because there were significant differences in baseline
profiles in terms of aortic valve morphology and the size of the
aorta.
However, the number of patients in the aorta replacement group
was too small, 70 patients only. Therefore, an adequate statistical
status method, including propensity score matching, was nearly
impossible. We could only obtain less than 50 pairs of patients if
you had a matching technique.
And furthermore, there was only 1 aortic event; therefore,
multivariate analysis was also impossible. Therefore, our study
may be better viewed as a study evaluating the later course of
AVR alone in the moderately dilated ascending aorta, mostly in
40 to 50 mm in our data set, and the second aim may be the
assessment of a safety profile of an additional aortic procedure.
Dr Sundt. I agree with you. I think that the most interesting
group is actually the control group, the AVR-alone group.
Second, there were 13 patients with unknown cause of death.
What happens to your analysis if you assume that all of these
deaths were due to aortic complications? Do you come to the
same conclusion?
Dr Kim. Thank you. Thirteen patients with unknown causes of
death were regarded as cardiac deaths, and when we broke down
the analysis according to the all-cause death and cardiac death,
there were no significant differences among the 3 groups. So I
believe the management strategy did not affect the survival.
Dr Sundt. And, third, there is significant controversy as to
whether the dilated aorta associated with a bicuspid valve is size
for size, diameter for diameter, fundamentally more prone to
complications than the aorta associated with a trileaflet valve.
In your control group, you have 139 patients withBAV.You have
shownwhat appears to be no difference in rate of growth, but just to
emphasize the point, do you see in the control group any evidence
for a difference in behavior at any given diameter between the aorta
associated with a trileaflet valve or a bicuspid valve?
Dr Kim. That is an important point. We try to compare in terms
of aortic events, aortic expansion rate, but we could not find any
significant difference between tricuspid valves and bicuspid.
Even when the analysis was broken down according to the aortic
diameter, we did not find any significant difference between the
2 valve morphology types.
Dr Sundt. Thank you much because I think, regardless of what
the histology shows and the theory may be, the bottom line always
is the clinical behavior. And sowe need these kinds of clinical data
to really know whether we are doing the right thing for our
patients. Thank you.
Dr Kim. Thank you very much.rdiovascular Surgery c Volume 146, Number 4 809
